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Abstract
Background Determining treatment response for patients with hidradenitis suppurativa (HS) can be challenging due to
limitations of current disease activity evaluations.
Objective Evaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (HiSCR) and its utility as
an outcome measure.
Methods Patients with baseline total abscess and inﬂammatory nodule count (AN count) of at least three and draining
ﬁstula count of 20 or fewer comprised the post hoc subpopulation analysed. HiSCR (at least a 50% reduction in total AN
count, with no increase in abscess count, and no increase in draining ﬁstula count relative to baseline) and HS-PGA
Response [Hidradenitis Suppurativa-Physician’s Global Assessment score of clear, minimal, or mild, with at least a 2-
grade improvement from baseline] were used to evaluate patient response after adalimumab treatment weekly, every
other week, or placebo (1 : 1 : 1).
Results The subpopulation included 132 (85.7%) patients; 70.5% women and 73.5% white. At week 16, HiSCR was
achieved by 54.5% receiving weekly adalimumab, 33.3% every other week, and 25.6% placebo and HS-PGA Response
was achieved by 20.5% receiving weekly adalimumab, 6.7% every other week and 2.3% placebo.
Conclusion HiSCR was more responsive to change than HS-PGA Response in this subpopulation.
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Introduction
Hidradenitis suppurativa (HS), also known as acne inversa, is a
painful, chronic, recurrent, inflammatory, debilitating skin dis-
ease1,2 that can be difficult to diagnose and to treat.1,3 Determi-
nation of response to treatment can also be challenging due to
limitations of currently available methods for evaluating disease
activity.
Despite the recognized need for more sensitive, accurate, effi-
cient and less complicated measures of disease severity and treat-
ment outcomes in clinical trials,4 dynamic evaluation of HS
severity has developed slowly over the past decade. The severity
of HS is frequently evaluated by means of Hurley Staging,5
although it was not designed to be a dynamic evaluation of a
treatment outcome. Of the few existing measures of HS disease
severity that can also detect treatment response, the most com-
mon dynamic measures are the Modified Sartorius Score6 and
the Physician’s Global Assessment (PGA).7
The Hidradenitis Suppurativa-PGA (HS-PGA) 6-point scale
was developed and used in a recent phase 2 clinical trial.8
Although HS-PGA simplified point calculation by means of an
objective total count of HS lesions, the stringent response
threshold of the study’s primary efficacy endpoint (achievement
of HS-PGA of clear, minimal, or mild with at least a 2-grade
improvement relative to baseline at Week 16) may have contrib-
uted to a reduced sensitivity to identify changes related to treat-
ment effect, reflected by the achievement of the endpoint by
only 20.5% of patients.
To address issues with HS-PGA and other HS scoring systems,
we developed a novel, validated, endpoint, Hidradenitis Suppurati-
va Clinical Response (HiSCR)9 that is responsive to improvement
in disease activity, simplifies the scoring process and increases the
sensitivity to detect HS-specific lesions during clinical evaluation.
The objective of the current post hoc analysis was to report the
treatment response utilizing the HiSCR endpoint, evaluate the util-
ity of HiSCR as a tool for clinical investigation, and to provide
context for clinicians on how to interpret this endpoint.
Methods
The subpopulation in this analysis of the placebo-controlled,
first 12 weeks of the phase 2 trial,8 included all randomized
patients who had a baseline abscess and inflammatory nodule
count (AN count) of 3 or more and draining fistula count of 20
or fewer. The primary analysis was the proportion of the sub-
population who achieved HiSCR (defined as at least a 50%
reduction in the total AN count with no increase in abscess
count and no increase in draining fistula count relative to base-
line) at week 12. The threshold of 50% reduction in AN count is
the defined level that is clinically appropriate and meaningful to
the patient regarding improvement in quality of life and pain
level.9,10 We compared HiSCR against the phase-2 trial’s pre-
specified, primary efficacy endpoint, the proportion of patients
who achieved treatment response using HS-PGA of clear, mini-
mal, or mild, with at least a 2-grade improvement relative to
baseline, henceforth referred to as HS-PGA Response, which
indicated a positive treatment effect with adalimumab in HS
patients.8 The time to achieve HiSCR and AN count reduction
of at least 50%, 75% and 100% relative to baseline (AN50,
AN75, AN100, respectively) were also evaluated.
Statistical methods
The Cochran–Mantel–Haenszel (CMH) test with factors of
treatment and baseline Hurley staging (I/II vs. III, the study
stratification factor) were used to analyse categorical variables,
and non-responder imputation was used to impute missing data.
The stratified log-rank test was used to analyse time to reach
HiSCR, where patients who completed or discontinued the first
16 weeks of the study without achieving HiSCR were censored
at their last evaluation. All statistical tests were 2-sided with the
significance level of 0.05. Safety was also analysed.
Results
Of the 154 patients randomized in the phase 2 study, the major-
ity (92.4%) completed, and 132 (85.7%) were included in the
current post hoc subpopulation. Of the 22 excluded patients, 16
had AN counts of <3 and 6 had draining fistula counts of >20.
Overall baseline demographics and clinical characteristics
(Table 1) were similar to the primary ITT study population,8 as
well as across the subpopulation treatment arms.
At each dose and time point, a greater percentage of
patients achieved treatment response by HiSCR compared
with HS-PGA Response (Fig. 1). Similar to HS-PGA
Response, a greater percentage of patients randomized to
weekly adalimumab achieved HiSCR compared with patients
randomized to adalimumab every other week, and to placebo
(Fig. 1). Differences between weekly adalimumab and placebo
treatment for HiSCR were significant at more time points
© 2015 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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than seen for HS-PGA Response; P < 0.001 at weeks 2, 4 and
12, and P = 0.007 at week 16. Improvement in AN count
overall and at different percentages of improvement (AN50,
AN75 and AN100) was observed at weeks 12 and 16 in both
adalimumab groups (Fig. 1).
As shown in Table 2, a significantly greater proportion of
patients with Hurley Stage II at baseline who were treated with
weekly adalimumab achieved HiSCR at week 16 compared with
patients receiving placebo (P = 0.004). A significant difference
was also seen in HS-PGA response for Hurley Stage II patients at
baseline who were treated with weekly adalimumab (P = 0.004).
Response by HiSCR at Week 16 was more evident than response
by HS-PGA, across all three baseline Hurley Stages and dose
groups.
As shown in Fig. 2, a shorter time to achieving HiSCR was
observed for patients treated with weekly adalimumab compared
with every other week, regardless of their baseline Hurley stage.
A difference in the time to achieving HiSCR was also observed
for patients treated with weekly adalimumab compared with pla-
cebo (significant for all patients, P = 0.0001, and patients with
Hurley Stage I/II at baseline, P = 0.0002).
Response was also evaluated by Sartorius Score.6 Median
(25th, 75th quartiles) change from baseline was 9.0 (33.0,
10.0) for patients receiving placebo, and 16.5 (48.0, 0.5)
and 32.0 (49.5, 8.0) for patients receiving adalimumab
every other week and weekly, respectively.
Safety findings have been previously presented.8
Discussion
Evaluation of treatment response for patients with HS can be
challenging due to limitations of currently available outcome
measures. This study explored the utility of the HiSCR, a novel,
validated, endpoint of treatment response for patients with HS,
by analysing a large, comprehensive data set of treatment out-
come measures in a post hoc assessment.
While other outcome measures appear to focus on disease
chronicity manifested by fistulas, scars and sinus tracts, the
HiSCR captures the more acute phase of HS activity that
involves inflammatory changes, as identified by inflammatory
nodule and abscess counts. The parameter of this study’s sub-
population (all randomized patients with baseline AN count of 3
or more and draining fistula count of 20 or fewer) are consistent
Table 1 Baseline demographics and clinical characteristics of the subpopulation
PBO (n = 43) ADA eow (n = 45) ADA ew (n = 44)
Age, years; mean (SD) 37.7 (12.01) 36.1 (12.77) 36.6 (10.68)
Sex, n (%)
Female 29 (67.4) 33 (73.3) 31 (70.5)
Male 14 (32.6) 12 (26.7) 13 (29.5)
Race, n (%)
White 31 (72.1) 34 (75.6) 32 (72.7)
Black 7 (16.3) 7 (15.6) 8 (18.2)
Other* 5 (11.6) 4 (8.9) 4 (9.1)
Weight, kg; mean (SD) 98.9 (24.30) 99.8 (28.15) 91.9 (21.66)
BMI, kg/m2; mean (SD) 34.7 (7.55) 35.2 (9.71) 31.9 (7.79)
≥30 (obese)† 33 (76.7) 30 (66.7) 24 (54.5)
≥40 (morbidly obese)† 13 (30.2) 14 (31.1) 8 (18.2)
Smokers (current or ever), n (%) 35 (81.4) 28 (62.2) 32 (72.7)
Disease duration, years; mean (SD) 13.3 (9.53) 11.4 (8.48) 12.1 (9.34)
HS-PGA, n (%)‡
Moderate 28 (65.1) 30 (66.7) 31 (70.5)
Severe/very severe 15 (34.9) 14 (31.1) 13 (29.5)
VAS skin pain (0–100); mean (SD) 60.2 (28.26) 53.3 (26.11) 51.7 (25.70)
Hurley stage, n (%)
I 6 (14.0) 7 (15.6) 8 (18.2)
II 24 (55.8) 25 (55.6) 25 (56.8)
III 13 (30.2) 13 (28.9) 11 (25.0)
Modiﬁed Sartorius Score; median 78.0 63.5 (n = 44)§ 65.5
*Includes Asian, American Indian/Alaska native, native Hawaiian or other Paciﬁc islander, other and multi-race.
†Obesity and morbid obesity levels deﬁned in Sturm, et al.11
‡One patient at baseline had mild HS according to HS-PGA.
§One patient had a missing value.
PBO, placebo; ADA, adalimumab; eow, every other week; ew, every week; SD, standard deviation; BMI, body mass index; HS-PGA, Hidradenitis
Suppurativa-Physician’s Global Assessment; VAS, visual analog scale.
© 2015 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
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with the population studied in the adalimumab HS phase 3 clini-
cal development program, which excludes mild disease that may
not be severe enough to warrant treatment with a biologic agent.
The primary component of HiSCR evaluation is the objective
and uncomplicated counting of HS lesions. Following ada-
limumab treatment, AN count showed marked improvement.
Patients receiving weekly adalimumab achieved significantly
greater improvement in AN counts (AN50, AN75 and AN100)
and greater mean improvement in AN count compared with
placebo, which are supportive of HiSCR as better able than HS-
PGA Response to differentiate treatment effect.
Response by HiSCR in the current analysis does not contra-
dict response by HS-PGA in the primary phase 2 population or
by Modified Sartorius Score, but rather represents a more sensi-
tive measure of change in disease activity, resulting in a more
accurate representation of patient response and treatment
evaluation.
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Figure 1 Achievement of HS-PGA response, HiSCR and AN count improvement for the subpopulation during Period 1: (a) proportion of
subpopulation achieving HS-PGA response. For ADA ew vs. PBO: *P = 0.010 at weeks 12 and 16. (b) Proportion of subpopulation
achieving response by HiSCR. For ADA ew vs. PBO: *P < 0.001 at weeks 2, 4 and 12; *P = 0.007 at week 16; For ADA eow vs. PBO:
†P = 0.009 at week 4 and †P = 0.042 at week 12. (c) proportion of subpopulation achieving AN50, AN75 and AN100. For ADA ew vs.
PBO: AN50, *P = 0.005 at week 12 and *P = 0.050 at week 16; AN75, *P = 0.033 at week 12; AN100, *P = 0.018 at week 12 and
*P = 0.010 at week 16. (d) Mean (SE) percent improvement in AN count; *P ≤ 0.001 for ADA ew vs. PBO at weeks 12 and 16. Non-
responder imputation. HS-PGA Response, Hidradenitis Suppurativa-Physician Global Assessment score of clear, minimal, or mild, with
at least a 2-grade improvement from baseline; HiSCR, Hidradenitis Suppurativa Clinical Response; AN, abscesses and inﬂammatory nod-
ules; PBO, placebo; ADA, adalimumab; eow, every other week; ew, every week.
Table 2 Proportion of the subpopulation achieving treatment
response at week 16 by baseline hurley stage
Hurley stage PBO
n = 43
n/N (%)
ADA eow
n = 45
n/N (%)
ADA ew
n = 44
n/N (%)
P-value
ew vs. PBO
Response by HiSCR
I 3/6 (50.0) 3/7 (42.9) 4/8 (50.0) >0.999
II 7/24 (29.2) 8/25 (32.0) 18/25 (72.0) 0.004*
III 1/13 (7.7) 4/13 (30.8) 2/11 (18.2) 0.576
HS-PGA response
I 1/6 (16.7) 1/7 (14.3) 0/8 (0) 0.429
II 0/24 (0) 2/25 (8.0) 8/25 (32.0) 0.004*
III 0/13 (0) 0/13 (0) 1/11 (9.1) 0.458
*Statistically signiﬁcant difference.
Non-responder imputation.
PBO, placebo; ADA, adalimumab; eow, every other week; ew, every
week; HiSCR, Hidradenitis Suppurativa Clinical Response; HS-PGA, Hid-
radenitis Suppurativa-Physician’s Global Assessment.
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Although our analysis found that patients at Hurley Stage II
(moderate HS) appeared to benefit the most from treatment as
evaluated by both HiSCR and by HS-PGA, this result may have
been negatively influenced by the small number of patients at
Hurley Stages I and III. In addition, response of patients may
have been hidden by disease fluctuation or by disease chronicity.
We were unable to compare our results with response based on
Sartorius scoring, which lacks a defined upper limit or accepted
outcome for success. As with previously reported outcome mea-
sures of HS, the HiSCR does not take into account the size or
severity of individual lesions and does not measure how treat-
ment response affects a patient’s level of pain or quality of life.
Despite the limited number of patients in this study, HiSCR
demonstrated a meaningful difference, due to its enhanced sensi-
tivity to detect treatment effects. The execution of the HiSCR
relies on objective measurements, and, therefore, provides an
effective, practical and easy-to-use outcome measure for HS that
can be utilized in clinical trials as well as in clinical practice. Effi-
cacy analyses using HiSCR have been further examined in the lar-
ger, phase 3, PIONEER I and PIONEER II trials of adalimumab
treatment for patients with moderate to severe HS (clinicaltri-
als.gov, NCT01468207 and NCT01468233, respectively).
Conclusions
This post hoc analysis demonstrated that HiSCR was more
responsive in detecting changes in response to treatment than
HS-PGA Response in this subpopulation of patients, and may
represent a useful tool in clinical practice and research trials
when assessing the efficacy of HS therapy.
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